Early detection saves lives—and we at Nanox are focused on applying our proprietary medical imaging technology to make diagnostic medicine more accessible and affordable across the globe. Our vision is to increase early detection of medical conditions that are discoverable by X-ray, which we believe is key to increasing early treatment, improving health outcomes […]

  We are a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. Our proprietary targeted protein degradation platform, which we refer to as Pegasus, allows us to discover highly selective small molecule protein degraders with potent activity against disease-causing […]

  We have not selected any business combination target and we have not, nor has anyone on our behalf, initiated any substantive discussions, directly or indirectly, with any business combination target. We intend to focus our search for a target business in the energy and infrastructure sector in North America.

(Note: This blank check company is now known as Cohn Robbins Holdings Corp., according to an S-1/A filing with the SEC on Aug. 25, 2020. The size of the proposed IPO also doubled along with the name change – to 60 million units at $10 each, up from 30 million at $10 each. Please see […]

  We are a blank check company newly incorporated on June 4, 2020 as a Cayman Islands exempted company incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, which we refer to throughout this prospectus as our initial business combination. Although […]

  We are a newly organized blank check company incorporated in May 2020 as a Delaware corporation formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses, which we refer to throughout this prospectus as our initial business combination. While […]

We are a blank check company formed in 2018 that will seek to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses or assets, which we refer to throughout this prospectus as our initial business combination. We currently intend to concentrate our efforts on […]

  We intend to partner with founders, employees, and shareholders to provide capital and unlock liquidity in the long path to building an enduring business. We believe that our approach, which allows private companies to access the public markets without requiring an initial public offering (an “IPO”), will help facilitate the discovery and development of […]

(Note: In an S-1/A filing dated Sept. 21, 2020, this blank check company changed its focus to healthcare; its previous S-1/A dated Aug. 26, 2020, stated a focus on the cannabis industry. The company announced the pricing of its IPO on Oct. 8, 2020. The IPO was priced on Oct. 7, 2020, at 7 million […]

We intend to focus on companies that have an aggregate enterprise value of approximately $500 million to $2 billion, are U.S.-based, have excellent management teams and good growth potential, and would benefit from access to capital to fund organic growth or acquisitions.